BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 31968199)

  • 1. UTILITY OF AFIRMA GENE EXPRESSION CLASSIFIER FOR EVALUATION OF INDETERMINATE THYROID NODULES AND CORRELATION WITH ULTRASOUND RISK ASSESSMENT: SINGLE INSTITUTIONAL EXPERIENCE.
    Sultan R; Levy S; Sulanc E; Honasoge M; Rao SD
    Endocr Pract; 2020 May; 26(5):543-551. PubMed ID: 31968199
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
    Jug RC; Datto MB; Jiang XS
    Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier.
    Hang JF; Westra WH; Cooper DS; Ali SZ
    Cancer Cytopathol; 2017 Sep; 125(9):683-691. PubMed ID: 28544601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
    Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
    Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier.
    Wong KS; Angell TE; Strickland KC; Alexander EK; Cibas ES; Krane JF; Barletta JA
    Thyroid; 2016 Jul; 26(7):911-5. PubMed ID: 27219469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk stratification of cytologically indeterminate thyroid nodules with nondiagnostic or benign cytology on repeat FNA: Implications for molecular testing and surveillance.
    Hall EA; Hartzband P; VanderLaan PA; Nishino M
    Cancer Cytopathol; 2023 May; 131(5):313-324. PubMed ID: 36792948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of cancer and the benign call rate of afirma gene classifier in
    Endo M; Sipos JA; Ringel MD; Porter K; Nagaraja HN; Phay JE; Shirley LA; Long C; Wright CL; Roll K; Nabhan FA
    Cancer Med; 2021 Feb; 10(3):1084-1090. PubMed ID: 33449450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
    Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
    Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
    [No Abstract]   [Full Text] [Related]  

  • 9. Young Investigator Challenge: Molecular testing in noninvasive follicular thyroid neoplasm with papillary-like nuclear features.
    Jiang XS; Harrison GP; Datto MB
    Cancer Cytopathol; 2016 Dec; 124(12):893-900. PubMed ID: 27893191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology.
    Zhu QL; Faquin WC; Samir AE
    AJR Am J Roentgenol; 2015 Oct; 205(4):861-5. PubMed ID: 26397337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UTILITY OF ULTRASOUND VERSUS GENE EXPRESSION CLASSIFIER IN THYROID NODULES WITH ATYPIA OF UNDETERMINED SIGNIFICANCE.
    Villabona CV; Mohan V; Arce KM; Diacovo J; Aggarwal A; Betancourt J; Amer H; Jose T; DeSantis P; Cabral J
    Endocr Pract; 2016 Oct; 22(10):1199-1203. PubMed ID: 27409819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
    Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
    Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. USING THE ATA AND ACR TI-RADS SONOGRAPHIC CLASSIFICATIONS AS ADJUNCTIVE PREDICTORS OF MALIGNANCY FOR INDETERMINATE THYROID NODULES.
    Ahmadi S; Herbst R; Oyekunle T; Jiang X'; Strickland K; Roman S; Sosa JA
    Endocr Pract; 2019 Sep; 25(9):908-917. PubMed ID: 31170369
    [No Abstract]   [Full Text] [Related]  

  • 14. American Thyroid Association Sonographic Risk and Afirma Gene Expression Classifier Alone and in Combination for the Diagnosis of Thyroid Nodules with Bethesda Category III Cytology.
    Arosemena M; Thekkumkattil A; Valderrama ML; Kuker R; Castillo RP; Sidani C; Gonzalez ML; Casula S; Kargi AY
    Thyroid; 2020 Nov; 30(11):1613-1619. PubMed ID: 32364010
    [No Abstract]   [Full Text] [Related]  

  • 15. Suggesting the cytologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A retrospective analysis of atypical and suspicious nodules.
    Strickland KC; Howitt BE; Barletta JA; Cibas ES; Krane JF
    Cancer Cytopathol; 2018 Feb; 126(2):86-93. PubMed ID: 28914983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing.
    Munoz-Zuluaga CA; Heymann JJ; Solomon JP; Patel A; Siddiqui MT; Scognamiglio T; Gokozan HN
    Am J Clin Pathol; 2024 May; 161(5):463-468. PubMed ID: 38104250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comprehensive Study on the Diagnosis and Management of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
    Alzumaili BA; Krumeich LN; Collins R; Kravchenko T; Ababneh EI; Fisch AS; Faquin WC; Nosé V; Martinez-Lage M; Randolph GW; Gartland RM; Lubitz CC; Sadow PM
    Thyroid; 2023 May; 33(5):566-577. PubMed ID: 36960710
    [No Abstract]   [Full Text] [Related]  

  • 18. Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology?
    Yang SE; Sullivan PS; Zhang J; Govind R; Levin MR; Rao JY; Moatamed NA
    Cancer Cytopathol; 2016 Feb; 124(2):100-9. PubMed ID: 26422098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COMMUNITY ENDOCRINE SURGICAL EXPERIENCE WITH FALSE-NEGATIVE AFIRMA GEC
    Harrell RM; Eyerly-Webb SA; Pinnar NE; Golding AC; Edwards CM; Bimston DN
    Endocr Pract; 2018 Jul; 24(7):622-627. PubMed ID: 29688761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.
    Lastra RR; Pramick MR; Crammer CJ; LiVolsi VA; Baloch ZW
    Cancer Cytopathol; 2014 Oct; 122(10):737-44. PubMed ID: 25123499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.